BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

You can have a reaction to various foods, but it’s not always an allergy – the difference lies with your immune system.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Regeneron has largely relied on two main products to drive top-line growth in recent years. One is Dupixent, an eczema treatment whose rights it shares with Sanofi, based in France. The other is ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

have fueled the top line for Sanofi and Regeneron. SNY and REGN are working to expand the drug’s label further. The FDA earlier approved Dupixent for chronic obstructive pulmonary disease (COPD).

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Regeneron loses key defense in COVID-19 treatment patent lawsuit Legalcategory· October 4, 2024 The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent ...